
|Videos|January 21, 2022
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the discussion, Lepor explained inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Novo Nordisk–Eli Lilly GLP-1 Ad Suit
2
Overlooked Coronavirus Protein May Drive Cytokine Storm, Cardiac Injury in Severe COVID-19
3
8 PDUFA Dates to Watch in Fall and Winter 2026
4
FDA Grants Fast Track Designation to ERAS-0015 for Metastatic Pancreatic Cancer
5


































































































